Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
Inclusion Criteria:
Exclusion Criteria:
medinfo@kitepharma.com844-454-5483(1-844-454-KITE)
St Louis, Missouri 63110, United States
Hackensack, New Jersey 07601, United States
New York, New York 10021, United States
Chapel Hill, North Carolina 27514, United States
San Antonio, Texas 782229, United States